Literature DB >> 17461424

Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules.

Conan J Fee1.   

Abstract

Therapeutic proteins conjugated with branched poly(ethylene glycol) (PEG) have extended in vivo circulation half-lives compared to linear PEG-proteins, thought to be due partly to a greater hydrodynamic volume of branched PEG-proteins, which reduces the glomerular sieving coefficient. In this paper, viscosity radii of PEGylated alpha-lactalbumin (M(r) = 14.2 kDa) and bovine serum albumin (M(r) = 67 kDa) prepared with linear and branched PEGs (with nominal molecular weights 5, 10, 20 and 40 kDa) were compared experimentally using size exclusion chromatography (SEC). PEG adduct:protein molecular weight ratios of the PEGylated proteins covered the range 1:12 to 6:1. Direct comparisons of experimentally measured viscosity radii were found to be misleading due to differences between actual and nominal molecular weights of the PEG reagents used. Comparison with predicted viscosity radii shows that there is no significant difference between the viscosity radii of branched and linear PEG-proteins having the same total molecular weight of PEG adducts. Therefore, longer in vivo circulation half-lives of branched PEG-proteins compared to linear PEG-proteins are not explained by size difference. It is also calculated that the molecular size cut-off for glomerular filtration, 60 A for a 30 kDa PEG, matches the 30-50 A size range for the pores of the glomerular basement membrane. Finally, it is confirmed that prediction of PEG-protein viscosity radii should be based upon conservation of the total PEG adduct surface area to volume ratio for both linear and branched PEG-proteins regardless of PEGylation extent. (c) 2007 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17461424     DOI: 10.1002/bit.21482

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  15 in total

1.  Controllable inhibition of cellular uptake of oxidized low-density lipoprotein: structure-function relationships for nanoscale amphiphilic polymers.

Authors:  Nicole M Iverson; Sarah M Sparks; Bahar Demirdirek; Kathryn E Uhrich; Prabhas V Moghe
Journal:  Acta Biomater       Date:  2010-02-17       Impact factor: 8.947

Review 2.  Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.

Authors:  Yulia Vugmeyster; John Harrold; Xin Xu
Journal:  AAPS J       Date:  2012-07-14       Impact factor: 4.009

3.  A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.

Authors:  Li Zheng; Mao Ping Li; Zhong Ping Gou; Ying Wang; Nan Xu; Yong Ming Cai; Hua Luo
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

4.  Structure of a PEGylated protein reveals a highly porous double-helical assembly.

Authors:  Giada Cattani; Lutz Vogeley; Peter B Crowley
Journal:  Nat Chem       Date:  2015-09-07       Impact factor: 24.427

5.  Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.

Authors:  Roni Mamluk; Irvith M Carvajal; Brent A Morse; Henry Wong; Janette Abramowitz; Sharon Aslanian; Ai-Ching Lim; Jochem Gokemeijer; Michael J Storek; Joonsoo Lee; Michael Gosselin; Martin C Wright; Ray T Camphausen; Jack Wang; Yan Chen; Kathy Miller; Kerry Sanders; Sarah Short; Jeff Sperinde; Gargi Prasad; Stephen Williams; Robert Kerbel; John Ebos; Anthony Mutsaers; John D Mendlein; Alan S Harris; Eric S Furfine
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

Review 6.  To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.

Authors:  Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia
Journal:  Adv Drug Deliv Rev       Date:  2021-12-10       Impact factor: 15.470

7.  Bioactivity and circulation time of PEGylated NELL-1 in mice and the potential for osteoporosis therapy.

Authors:  Yulong Zhang; Omar Velasco; Xinli Zhang; Kang Ting; Chia Soo; Benjamin M Wu
Journal:  Biomaterials       Date:  2014-05-10       Impact factor: 12.479

Review 8.  Protease-resistant peptide design-empowering nature's fragile warriors against HIV.

Authors:  Matthew T Weinstock; J Nicholas Francis; Joseph S Redman; Michael S Kay
Journal:  Biopolymers       Date:  2012       Impact factor: 2.505

9.  Multimeric peptide-based PEG nanocarriers with programmable elimination properties.

Authors:  Simi Gunaseelan; Shahriar Pooyan; Peiming Chen; Mahta Samizadeh; Matthew S Palombo; Stanley Stein; Xiaoping Zhang; Patrick J Sinko
Journal:  Biomaterials       Date:  2009-07-31       Impact factor: 12.479

10.  Impact of Tuning the Surface Charge Distribution on Colloidal Iron Oxide Nanoparticle Toxicity Investigated in Caenorhabditis elegans.

Authors:  Loredana Amigoni; Lucia Salvioni; Barbara Sciandrone; Marco Giustra; Chiara Pacini; Paolo Tortora; Davide Prosperi; Miriam Colombo; Maria Elena Regonesi
Journal:  Nanomaterials (Basel)       Date:  2021-06-11       Impact factor: 5.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.